Accumulation of TOX high mobility group box family member 3 promotes the oncogenesis and development of hepatocellular carcinoma through the MAPK signaling pathway

Yufu Peng, Jing Yu, Fei Liu, Leyi Tang, Bo Li, Wei Zhang, Kefei Chen, Haili Zhang, Yonggang Wei, Xuelei Ma, Hubing ShiMedComm 2024 · DOI

TL;DR

This study identifies TOX3 as a key driver of hepatocellular carcinoma (HCC) progression, particularly in cases with microvascular invasion (MVI). TOX3 promotes tumor growth and metastasis by activating MAPK and EMT signaling pathways, and its degradation is regulated by the E3 ligase TRIM56. This work highlights TOX3 as a potential therapeutic target for aggressive HCC.

What Problem Does This Paper Address?

Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths, and microvascular invasion (MVI) is a strong indicator of poor prognosis and increased metastasis in HCC patients. However, the underlying molecular mechanisms that contribute to the aggressive behavior of MVI-positive HCC remain poorly understood. This knowledge gap hinders the development of targeted therapies for these high-risk patients. This paper aims to identify key genes and signaling pathways involved in the oncogenesis and development of MVI-positive HCC to uncover potential therapeutic targets.

Methods

The researchers employed a multi-pronged approach:

  • RNA Sequencing (RNA-seq): Used to compare gene expression profiles between MVI-positive HCC tissues, MVI-negative HCC tissues, and adjacent normal liver tissues. This was crucial for identifying differentially expressed genes (DEGs).
  • In vitro studies: Utilized HCC cell lines (HCCLM3) to investigate the functional roles of TOX3. Techniques included CRISPR/Cas9 for gene knockout, lentivirus transduction for gene overexpression, CCK-8 assays for proliferation, colony formation assays, wound healing assays, and Transwell migration assays to assess cell growth and invasiveness.
  • In vivo studies: Employed nude mouse models to evaluate the impact of TOX3 on tumor growth and metastasis. This involved subcutaneous tumor models, lung metastasis models, and liver orthotopic implantation models, with tumor volume, weight, and metastasis assessed.
  • Immunoprecipitation coupled with Mass Spectrometry (IP-MS): Used to identify proteins that interact with TOX3, particularly those involved in its degradation.
  • Western Blot (WB) and Immunohistochemistry (IHC): Standard techniques to confirm protein expression levels and localization of key molecules in signaling pathways.
  • Bioinformatics Analysis: Including Gene Set Enrichment Analysis (GSEA) to identify enriched signaling pathways and Robust Rank Aggregation (RRA) to pinpoint robust target genes.

Datasets

  • Clinical Samples: HCC tissues and paired adjacent normal liver tissues from patients who underwent selective curative hepatectomy. These were divided into sequencing groups and validation cohorts.
  • TCGA Database: Utilized for statistical analysis of TOX3 and IGFBP3 expression and their correlation with patient prognosis (overall survival and disease-free survival).
  • GTEx Dataset: Used for obtaining mRNA expression data of normal liver tissue.

Key Insights and Ideas

  • TOX3 as a "bad actor" in aggressive HCC: The study strongly implicates TOX3 as a critical driver of oncogenesis and metastasis in MVI-positive HCC, linking its overexpression to poorer patient outcomes.
  • MAPK and EMT pathways are central: TOX3 appears to exert its pro-tumorigenic effects by directly influencing the MAPK and EMT signaling pathways, which are well-known for their roles in cell proliferation, migration, and invasion.
  • IGFBP3 as a key downstream target: The research identifies insulin-like growth factor binding protein 3 (IGFBP3) as a crucial downstream target of TOX3. TOX3's regulation of IGFBP3 is central to its ability to promote HCC progression.
  • TRIM56 as a regulator of TOX3 stability: The discovery that TRIM56, an E3 ligase, mediates the proteasomal degradation of TOX3 is a significant finding. This suggests a feedback loop where reduced TRIM56 leads to TOX3 accumulation, driving tumor growth.
  • Therapeutic potential: The findings point towards TOX3 and potentially TRIM56 as promising therapeutic targets for aggressive HCC, especially in patients with MVI.

Key Results

  • TOX3 is significantly upregulated in MVI-positive HCC tissues compared to MVI-negative HCC and normal tissues.
  • High TOX3 expression is associated with a worse prognosis in HCC patients, both in the study's cohort and in TCGA data.
  • Knocking out TOX3 in HCC cell lines (HCCLM3) significantly reduced proliferation and migration, while overexpression had the opposite effect.
  • In vivo studies showed that TOX3 knockout suppressed tumor growth and metastasis in mouse models, whereas TOX3 overexpression enhanced these processes.
  • TOX3 overexpression led to increased expression of key MAPK and EMT pathway proteins (e.g., p-ERK1/2, Vimentin, Snail, Cluding, Slug), while TOX3 knockdown decreased them.
  • IGFBP3 expression was directly regulated by TOX3, and its knockdown or overexpression mimicked or reversed the effects of TOX3 on HCC cell behavior.
  • TRIM56 knockdown led to increased TOX3 protein levels, suggesting TRIM56's role in TOX3 degradation.
  • TRIM56 expression was downregulated in HCC tissues, correlating with reduced ubiquitin-proteasome system activity.

Limitations and Future Work

  • Specificity of TOX3's role: While the study focuses on HCC, the authors acknowledge that TOX3 has been implicated in other cancers (breast, lung, colorectal). Further research could explore the broader roles of TOX3 in different cancer types.
  • Mechanism of TOX3-IGFBP3 interaction: The paper suggests TOX3 binds to the CRE site in the IGFBP3 promoter. However, a more detailed molecular investigation into this interaction could be beneficial.
  • Clinical translation: While TOX3 is identified as a potential therapeutic target, further preclinical and clinical studies are needed to develop and validate TOX3-targeting therapies.
  • TRIM56's broader role: The study highlights TRIM56's role in TOX3 degradation. Investigating the full spectrum of TRIM56's functions in HCC and its potential as a therapeutic target itself would be valuable.
  • Complex signaling networks: The study identifies key pathways, but the intricate interplay of various signaling molecules within these pathways and their interaction with TOX3 and IGFBP3 warrants further exploration.

Summary updated

Abstract

Microvascular invasion (MVI) has been widely valued in the field of liver surgery because MVI positivity indicates poor prognosis in hepatocellular carcinoma (HCC) patients. However, the potential molecular mechanism underlying the poor prognosis of MVI-positive HCC patients is unclear. Therefore, this study focused on identifying the key genes leading to poor prognosis in patients with a high degree of malignancy of HCC by examining the molecular signaling pathways in MVI-positive HCC patients. Through RNA sequencing, TOX high mobility group box family member 3 (TOX3) was demonstrated to be significantly highly expressed in MVI-positive HCC tissues, which was associated with poor prognosis. The results of in vivo and in vitro showed that TOX3 can promote the oncogenesis and development of HCC by targeting key molecules of the MAPK and EMT signaling pathways. The IP-MS results indicated that proteasome degradation of TOX3 in HCC cells is potentially mediated by a tripartite motif containing 56 (TRIM56, an E3 ligase) in HCC cells. Inhibiting TRIM56 enhances TOX3 protein levels. Overall, our study identified TOX3 as a key gene in the MAPK and EMT signaling pathways in HCC, and its overexpression confers significant proliferation and invasiveness to tumor cells.
BibTeX
@inproceedings{peng2024accumulation,
  author = {Yufu Peng and Jing Yu and Fei Liu and Leyi Tang and Bo Li and Wei Zhang and Kefei Chen and Haili Zhang and Yonggang Wei and Xuelei Ma and Hubing Shi},
  title = {{Accumulation of TOX high mobility group box family member 3 promotes the oncogenesis and development of hepatocellular carcinoma through the MAPK signaling pathway}},
  booktitle = {MedComm},
  year = {2024},
  doi = {10.1002/mco2.510},
}
Figure